Metastatic Renal Cell Carcinoma Market - Global Industry Analysis, Market Size, Share, Growth, Trends and Forecast, 2016 - 2021...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Metastatic Renal Cell Carcinoma market report covers research informatics related to Metastatic Renal Cell Carcinoma clinical trials, such as a listing of industry and sponsored clinical trials as well as new drug therapies.. Designed to be a resource both for patients interested in participating in Metastatic Renal Cell Carcinoma clinical trials and for research professionals.. The report, "Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016″ provides an overview of Metastatic Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Renal Cell ...http://beforeitsnews.com/healthcare/2016/11/metastatic-renal-cell-carcinoma-market-global-industry-analysis-market-size-share-growth-trends-and-forecast-2016-2021-2489639.html
Renal Cell Carcinoma Epidemiology and Market Analysis 2017 with Forecast to 2023 | Healthcare
List of Tables. Table 1: Clinical subtypes of Indication. Table 2: Risk Factors. Table 3: Prevalence cases (%) Region wise. Table 4: Sources used for forecasting the data. Table 5: Renal cell carcinoma Global Epidemiology, (2013-2023). Table 6: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), US (2013-2023). Table 7: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), US (2013-2023). Table 8: Prevalent Cases By Renal cell carcinoma Sub-population, US (2013-2023). Table 9: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), United Kingdom (2013-2023). Table 10: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), United Kingdom (2013-2023). Table 11: Prevalent Cases ...http://beforeitsnews.com/healthcare/2017/03/renal-cell-carcinoma-epidemiology-and-market-analysis-2017-with-forecast-to-2023-2507259.html
Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC) | BenthamScience
Title:Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). VOLUME: 8 ISSUE: 3. Author(s):Zofia F. Bielecka, Anna M. Czarnecka, Wojciech Solarek, Anna Kornakiewicz and Cezary Szczylik. Affiliation:Laboratory of Molecular Oncology, Department of Oncology, Military Institute of Medicine in Warsaw, Szaserów 128, 04-141 Warsaw, Poland.. Keywords:Acquired drug resistance, tyrosine kinase inhibitors, sunitinib, sorafenib, pazopanib, axitinib, tivozanib, epithelialmesenchymal transition, angiogenic switch, anti-angiogenic therapy, clear-cell renal cell carcinoma, non-genetic resistance mechanisms.. Abstract:Clear - cell renal cell carcinoma (ccRCC) is a histological subtype of renal cell carcinoma - the most ...http://www.eurekaselect.com/120239/article
Slide for IHC-Human Kidney Slide (Clear Cell Renal Cell Carcinoma) (5 slides/pk)-Alpha Diagnostic International Inc.
Human Kidney Slide (Clear Cell Renal Cell Carcinoma) (5 slides/pk) Slide for IHC HTS-10405 Human Kidney Slide (Clear Cell Renal Cell Carcinoma) (5 slides/pk) Slide for IHC HTS-10405http://4adi.com/ccp21595-human-kidney-slide-28clear-cell-renal-cell-carcino-slide-for-ihc-hts-10405.htm
Fluid intake and incidence of renal cell carcinoma in UK women - Oxford Cancer Epidemiology Unit (CEU)
Background:It has been suggested that the apparent protective effect of alcohol intake on renal cell carcinoma may be due to the diluting effect of carcinogens by a high total fluid intake. We assessed the association between intakes of total fluids and of specific beverages on the risk of renal cell carcinoma in a large prospective cohort of UK women.Methods:Information on beverage consumption was obtained from a questionnaire sent 3 years after recruitment into the Million Women Study. Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for renal cell carcinoma associated with beverage consumption adjusted for age, region of residence, socioeconomic status, smoking, and body mass index.Results:After an average of 5.2 years of follow-up, 588 cases of renal cell ...https://www.ceu.ox.ac.uk/publications/149773
Nivolumab Superior to Everolimus for Previously-treated Renal Cell Carcinoma - http://cyto.blogs.sapo.pt
Bristol-Myers Squibb has announced the early closure of its phase 3 CheckMate-025 trial evaluating nivolumab (Opdivo) compared with everolimus for the treatment of previously-treated patients with advanced or metastatic renal cell carcinoma.. The study was stopped early because an independent Data Monitoring Committee assessment found that nivolumab is superior to everolimus in this patient population.. "The results of CheckMate-025 mark the first time an Immuno-Oncology agent has demonstrated a survival advantage in advanced renal cell carcinoma, a patient group that currently has limited treatment options," said Michael Giordano, senior vice president, Head of Development, Oncology, Bristol-Myers Squibb. "Through our Opdivo clinical development program, we aim to redefine treatment expectations for patients with advanced RCC by providing improved survival.". For the open-label trial, 821 previously-treated ...http://cyto.blogs.sapo.pt/nivolumab-superior-to-everolimus-for-132437
Evaluation of Nuclear Morphometry and Ki-67 Index in Clear Cell Renal Cell Carcinomas: a Five-Year Study
Background and objective: Clear Cell Renal Cell Carcinoma (CCRCC) is the most common adult renal neoplasm. Staging and grading of RCC are important predictors of survival. Fuhrman nuclear grading is widely used for CCRCC, the subjective nature of which has prompted more objective methods to evaluate nuclear features. Furthermore, Ki-67, a reliable marker of cellular proliferation may provide another variable for assessment of the biological behavior of RCC. The aim of this research was to study nuclear morphometry and Fuhrman nuclear grading of clear cell RCC, and to assess their relationship with the Ki-67 index. Methods: Hematoxylin and eosin slides of forty cases of CCRCC were retrieved and studied for pathologic variables, including Fuhrman nuclear grade, pathological tumor and node stage. Nuclear morphometric analysis was performed using computer-assisted image analysis. The ...http://ijp.iranpath.org/article_24873.html
Cell Cycle Regulation in Human Renal Cell Carcinoma
ABSTRACT. Cell cycle regulation in human renal cell carcinoma. Ylva Hedberg, Departments of Medical Biosciences, Pathology, and Surgical and. Perioperative Sciences, Urology Andrology, Umeå University, Sweden. Deregulated growth control is a hallmark of neoplasia potentially caused by aberrant expression of cell cycle regulatory proteins. The importance of such aberrations in human renal cell carcinoma (RCC) has not been fully clarified. Therefore, the protein expressions of several G1/S regulatory proteins in human RCC were evaluated and their relation to clinico-pathological data was examined.. Western blotting and immunohistochemistry were used to detect the proteinexpression of cyclin D1, D3, and E in 80 RCCs. Most tumors expressed higher levels of cyclin D1 (75%) and cyclin E (65%) compared to corresponding normal kidney cortex. In contrast, only 16 % of the tumors had ...http://umu.diva-portal.org/smash/record.jsf?pid=diva2:143327
New trial results on pazopanib have important implications for patients with advanced renal cell carcinoma | ESMO
The results of a phase III trial comparing two commonly used drugs in the second-line treatment of renal cell carcinoma suggest that temsirolimus does not improve survival over sorafenib in the second line setting.. The two drugs inhibit different targets: temsirolimus targets mTOR, which regulates cell growth and proliferation, while sorafenib inhibits several tyrosine kinases, including VEGF receptors.. This is the first head-to-head phase III trial comparing a VEGF inhibitor to an mTOR inhibitor in renal cell carcinoma, reporting final results. Hence, this trial will have important treatment implications for patients and physicians, noted Dr Thomas Hutson from Texas Oncology-Baylor Charles A Sammons Cancer Center in Texas, USA.. Temsirolimus had demonstrated an overall survival benefit compared to interferon alfa in previously untreated patients with advanced renal ...http://www.esmo.org/Conferences/Past-Conferences/ESMO-2012-Congress/News-Press-Releases/Congress-News/New-trial-results-on-pazopanib-have-important-implications-for-patients-with-advanced-renal-cell-carcinoma
Temsirolimus Prolongs Survival of Patients With Advanced Renal Cell Carcinoma | Cancer Network | The Oncology Journal
Preliminary data from an interim analysis of an ongoing phase III clinical trial of investigational temsirolimus (CCI-779) for the treatment of advanced renal cell carcinoma showed that single-agent therapy with temsirolimus significantly increased overall survival as a first-line treatment of patients with advanced disease and poor-risk features compared to interferon-alpha, a treatment for advanced renal cell carcinoma. In the trial, patients who were treated with temsirolimus alone experienced a 3.6-month, or 49%, increase in median overall survival time compared with patients treated with interferon-alpha alone (10.9 vs 7.3 months, P = .0069). 1http://www.cancernetwork.com/articles/temsirolimus-prolongs-survival-patients-advanced-renal-cell-carcinoma
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma - Full Text View - ClinicalTrials.gov
Patients with advanced renal cell carcinoma (RCC) are classified according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria in three risk-groups: favourable, intermediate and poor. To our knowledge there is only one study which examined the poor risk group (Hudes et al.), which led to the approval of temsirolimus in this population. However temsirolimus demonstrated a low response rate of 8.6% according to Response Evaluation Criteria In Solid Tumor (RECIST) criteria and a Progression free Survival (PFS) of 5.5 months and not all patients are suitable for temsirolimus treatment.. Thus, in clinical routine high-risk patients are also treated with multi Tyrosinkinase Inhibitors (mTKI). To date, a prospective data acquisition and control of effectiveness of a mTKI-treatment in high-risk patients has not been conducted.. Pazopanib was recently approved for the first-line treatment of advanced renal cell ...https://clinicaltrials.gov/ct2/show/NCT01521715?recr=Open&cond=%22Carcinoma%22&rank=9
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma - Study...
Thomas E. Hutson, Long H. Dang, Richard C. Lauer, Alexander Starodub, Ralph J. Hauke, Matt D. Galsky, Kathryn A. Bylow, Theodore Logan, Charles Lance Cowey, David C. Bibby, Gabriel Kremmidiotis, Elizabeth E. Doolin, Tina C. Lavranos, Guru Sonpavde, Noah M. Hahn, Christopher Sweeney, John Sarantopoulos. Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors. J Clin Oncol 30, 2012 (suppl; abstr 4603) http://www.asco.org/ASCOv2/Meetings/Abstracts&vmview=abst_detail_view&confID=114&abstractID=91911 ...https://clinicaltrials.gov/ct2/show/results/NCT01034631?term=BNC105P&rank=1
Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma.
PURPOSE: We evaluated the effect of roscovitine (Sigma-Aldrich®), a pharmacological inhibitor of cyclin dependent kinase, on renal cell carcinoma cell lines in vitro. MATERIALS AND METHODS: We exposed several renal cell carcinoma cell lines to roscohttp://www.biomedsearch.com/nih/Pharmacological-Inhibition-Cyclin-Dependent-Kinases/20850841.html
Metastatic Renal Cell Carcinoma, Pipeline Review, H1 2015
List of Tables. Number of Products under Development for Metastatic Renal Cell Carcinoma, H1 2015 12. Number of Products under Development for Metastatic Renal Cell Carcinoma-Comparative Analysis, H1 2015 13. Number of Products under Development by Companies, H1 2015 15. Number of Products under Development by Companies, H1 2015 (Contd..1) 16. Number of Products under Development by Companies, H1 2015 (Contd..2) 17. Number of Products under Investigation by Universities/Institutes, H1 2015 18. Comparative Analysis by Late Stage Development, H1 2015 19. Comparative Analysis by Clinical Stage Development, H1 2015 20. Comparative Analysis by Early Stage Development, H1 2015 21. Comparative Analysis by Unknown Stage Development, H1 2015 22. Products under Development by Companies, H1 2015 23. Products under Development by Companies, H1 2015 (Contd..1) 24. Products under Development by Companies, H1 2015 ...https://www.kenresearch.com/healthcare/pharmaceuticals/metastatic-renal-cell-carcinoma-pipeline/8826-91.html
Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus - University of...
Purpose: Temsirolimus is an effective treatment for renal cell carcinoma. It is associated with increases in serum cholesterol, triglyceride, and glucose. We investigated whether changes of these biomarkers could predict its efficacy. Experimental Design: We examined serial measurements of cholesterol, triglycerides, and glucose from patients randomized to IFN or temsirolimus in the Global Advanced Renal Cell Carcinoma Trial. Using time-dependent proportional hazards models, we quantified the association between changes in these biomarkers from baseline with overall survival (OS) and progression-free survival (PFS). We also assess the extent to which changes of these biomarkers predict the effects of temsirolimus on survival. Results: Temsirolimus was associated with larger mean increases in cholesterol (1.02 mmol/L; P | 0.0001), triglycerides (0.32 mmol/L; P = 0.0008), and glucose (1.28 mmol/L; P | ...https://www.phc.ox.ac.uk/publications/435026
Registry For Temsirolimus Sunitinib And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC) Mantle Cell...
New life-saving treatments for Mantle-cell | gastrointestinal stroma tumors | carcinoma | renal cell | lymphoma | advanced in clinical trial on Registry For Temsirolimus Sunitinib And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC) Mantle Cell Lymphoma (MCL) And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]http://www.centerwatch.com/clinical-trials/listings/45963/carcinoma-renal-cell-advanced-registry-temsirolimus-sunitinib/?&geo_lat=52.6380924&geo_lng=9.2084155&radius=10
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell...
Treatment of the metastatic renal cell carcinoma (mRCC) has experienced fundamental changes within a very short period of time. In the past few years, introduction of various new substances for the treatment of mRCC has therefore resulted in new scientific research questions. Temsirolimus and sunitinib are current standard therapies in the first-line treatment of mRCC. Inlyta® is a new substance that was developed for the treatment of mRCC after failure of sunitinib or cytokines.. Since August 2009, Torisel® is available as another treatment option for patients with mantle cell lymphoma (MCL). In addition, Sutent® is used for patients with non-resectable / metastatic gastro-intestinal stroma tumors (GIST) after failure or intolerability of imatinib.. The routine use of drugs in the usual clinical setting faces additional challenges that generally cannot be completely reflected by clinical trials. Therefore, the purpose of this registry is to ...https://clinicaltrials.gov/ct2/show/NCT00700258?term=everolimus+AND+GIST&recr=Open&rank=1
Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy |...
The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line sunitinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (,12 months; p = 0.001), histological subtype (non-CC; p,0.05) and number of BMs (≥2; p,0.05) were significantly associated with OS in multivariate analysis. There were no cases of toxic death. One mRCC patient with BMs (1.7%) experienced treatment-related cerebral necrosis. All other toxicities included those commonly observed with VEGF-TKI therapy.. ...http://www.tumorijournal.com/article/07e1bc8c-72d6-4c23-aeff-df149d5783db
FDA Approves Opdivo for Renal Cell Carcinoma - UNM Comprehensive Cancer Center
The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600 mutation as well as advanced non-small cell lung cancer.. About Renal Cell Carcinoma. Each year in the United States, more than 61,000 people are diagnosed with kidney cancer. The most common type of kidney cancer is renal cell carcinoma (RCC), which starts in the lining of very small tubes (tubules) in the kidney. For people with advanced RCC (cancer that has spread to other parts of the body), targeted therapies can play an important role in treatment. Approximately 20-30% of patients with RCC will have metastases at diagnosis and as many as 40% will demonstrate metastasis after primary surgical treatment for localized RCC. With a 5-year ...http://cancer.unm.edu/2015/11/25/fda-approves-opdivo-for-renal-cell-carcinoma/
Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell...
This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases. The nameshttp://adisinsight.springer.com/trials/700255541?error=cookies_not_supported&code=63414c50-d037-4476-b211-a9a6e9c11978
Institute of Cancer Research Repository - Treatment selection in metastatic renal cell carcinoma: expert consensus
In metastatic renal cell carcinoma (mRCC), many factors influence clinical decisions, including histology, tumour burden, prognostic factors, comorbidities, and the ability of the patient to tolerate treatment. Progression-free survival (PFS) durations reported from randomized trials of targeted therapies vary considerably, in part because of differences in patient characteristics. For first-line therapy, an estimate of PFS with sunitinib, bevacizumab plus interferon, or sorafenib in a 'general' population is 8-9 months, but each regimen is suitable for different patient categories. For example, sunitinib is suitable for all-prognosis groups, particularly younger, fitter patients; pazopanib for patients with a good or intermediate prognosis; bevacizumab plus interferon for good-prognosis patients or those with indolent disease; and sorafenib for patients at all prognostic risk levels, particularly the elderly and those with comorbidities. Sequential therapy ...http://publications.icr.ac.uk/11739/
A retrospective study to evaluate the effect of Nivolumab in patients with metastatic non-clear cell renal cell carcinoma ...
This retrospective study evaluated the effect of Nivolumab in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated in a national earlyhttp://adisinsight.springer.com/trials/700289383?error=cookies_not_supported&code=248d8254-c626-484e-9e7e-b9e4f36fa5c2
Prognostic factors of resected metastatic lung tumor originated from renal cell carcinoma.
We performed retrospective analysis of 22 cases who received pulmonary resection of metastases originated from renal cell carcinoma between 1997 and 2011. Patients comprised 18 men and 4 women with a mean age of 63 years (range, 39~79). The total pulmonary resection was 30 times, lobectomy was performed 5 times and wedge resection was 25 times. The 5-year overall survival was 35% and 10-year overall survival was 26%. Prognostic factors were histology of renal cell carcinoma (G1, 2 group vs. G3 group; 2-year survival rate was 69% and 20% respectively, p=0.023) and disease-free interval (less than 24 months vs. more than 24 months; 5-year disease-free survival rate was 22% and 75% respectively, p=0.019) in univariate analysis. Only disease-free interval showed significant difference (p=0.037) in multivariate analysis. This study demonstrated that aggressive surgical resection of pulmonary metastasis from ...http://pubtransformer.com/Pubmed?pmid=23575177
Metastatic renal cell carcinoma to the thyroid gland: a clinicopathologic study of 36 cases.
Abstract BACKGROUND: Clear cell tumors of the thyroid gland in general are uncommon. Metastatic renal cell carcinoma (RCC) to the thyroid gland is a rare occurrence but must be con..https://www.omicsonline.org/references/metastatic-renal-cell-carcinoma-to-the-thyroid-gland-a-clinicopathologic-study-of-36-cases-1433891.html
EUSA Pharma Receive Positive Opinion from The CHMP For tivozanib For The First-Line Treatment of Advanced Renal Cell Carcinoma...
EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorisation of FOTIVDA (tivozanib) for the management of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland. If approved, it will be indicated for the first-line treatment of adult patients with advanced RCC and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.1 RCC is the most common form of kidney cancer,2 which accounts for an estimated 49,000 deaths in Europe each year.3 It is expected to be one of the fastest increasing cancers over the next ten years.4 Vascular endothelial growth factor receptor tyrosine kinase ...https://www.sttinfo.fi/tiedote/eusa-pharma-receive-positive-opinion-from-the-chmp-for-tivozanib-for-the-first-line-treatment-of-advanced-renal-cell-carcinoma-in-the-european-union?publisherId=58763726&releaseId=62166611